Evoke Pharma (EVOK) stock soared 168% after the company won a US patent for Gimoti, its nasal spray for gastroparesis, extending exclusivity to 2036. The drug helps patients with delayed stomach emptying, especially when oral meds fail. Q1 sales doubled year-over-year to $3.1 million. Retail sentiment turned 'extremely bullish' on Stocktwits, with traders piling in.